

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	<b>Application Number</b>		10658873	
	<b>Filing Date</b>		2003-09-05	
	<b>First Named Inventor</b>	Michael S. Kopreski		
	<b>Art Unit</b>	1634		
	<b>Examiner Name</b>	Lu, Frank Wei Min		
<b>Attorney Docket Number</b>		00-1312-K		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10658873
Filing Date	2003-09-05
First Named Inventor	Michael S. Kopreski
Art Unit	1634
Examiner Name	Lu, Frank Wei Min
Attorney Docket Number	00-1312-K

/F.L./	1	Vitetta et al. (1991), "Immunotoxins," In: Biologic Therapy of Cancer, (Ed. DeVita et al.) Lippincott: Philadelphia pp. 482-495.	<input type="checkbox"/>
	2	Wang et al. (1989), "Quantitation of mRNA by the polymerase chain reaction," Proc. Natl. Acad. Sci. U. S. A. 86: 9717-9721.	<input type="checkbox"/>
	3	Wieczorek et al. (1987), Cancer Research 47: 6407-6412.	<input type="checkbox"/>
	4	Wieczorek et al. (1989), Schweiz med Wschr 119: 1342-1343.	<input type="checkbox"/>
	5	Wieczorek et al. (1985), Proc. Natl. Acad. Sci. U. S. A. 82: 3455-3459.	<input type="checkbox"/>
	6	Wiedmann et al. (1994), PCR Methods Applic. 3: 551-564.	<input type="checkbox"/>
	7	Yanuck et al. (1993), Cancer Research 52: 3257-3261.	<input type="checkbox"/>
	8	Rohde et al. (2000), Clin. Cancer Res. 6: 4803-4809.	<input type="checkbox"/>
	9	Keller et al. (1993), PCR Methods and Applications 3: 32-38.	<input type="checkbox"/>
	10	Nolte et al. (1994), J. Clin. Microbiology 32: 519-520.	<input type="checkbox"/>
	11	Schmidt et al. (1995), J. Med. Virology 47: 153-160.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10658873
Filing Date	2003-09-05
First Named Inventor	Michael S. Kopreski
Art Unit	1634
Examiner Name	Lu, Frank Wei Min
Attorney Docket Number	00-1312-K

/F.L./	12	Agliullina et al. (1988), Eksp. Onkol (USSR) 10(4), English abstract.	<input type="checkbox"/>
	13	Schwarz et al. (1995), Res. Virol (Paris) 146(5), English abstract.	<input type="checkbox"/>
	14	Kato et al. (1993), Hepatology 18(1), abstract.	<input type="checkbox"/>
	15	Glick et al. (1994), Molecular biotechnology: Principles and applications of recombinant DNA, ASM Press: Washington DC. Table of Contents for Molecular Diagnostics (8) and Vaccines and Therapeutic Agents (9).	<input type="checkbox"/>
	16	Persing et al (1993), Diagnostic molecular microbiology: Principles and applications, Amer. Soc. Microbiol. Washington DC, Table of Contents for Principles of Diagnostic Molecular Microbiology and Viral Pathogens.	<input type="checkbox"/>
	17	Southall et al. (1990), Br. J. Cancer 61: 89-95.	<input type="checkbox"/>
	18	Kopreski et al. (2001), Ann. N. Y. Acad. Sci 945: 172-178.	<input type="checkbox"/>
	19	Yan-Sanders et al. (2002), Cancer Letters 183: 215-220.	<input type="checkbox"/>
	20	Khimani et al. (2005), BioTechniques 38: 739-745.	<input type="checkbox"/>
	21	Schrader et al. (2002), BMC Cancer 2: 32.	<input type="checkbox"/>
	22	Fleischhacker et al. (2001), Ann. N. Y. Acad. Sci. 945: 179-188.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10658873
Filing Date		2003-09-05
First Named Inventor	Michael S. Kopreski	
Art Unit	1634	
Examiner Name	Lu, Frank Wei Min	
Attorney Docket Number	00-1312-K	

/F.L./	23	Burd et al. (1989), Proc. Natl. Acad. Sci. U. S. A. 86: 9788-9792.	<input type="checkbox"/>
	24	Burchill et al. (1995), Br. J. Cancer 71: 278-281.	<input type="checkbox"/>
	25	Lasheeb et al. (1997), Genitourinary Medicine 73(4): 303-305.	<input type="checkbox"/>
	26	Mermin et al. (1991), J. Infectious Diseases 164(4): 769-772.	<input type="checkbox"/>
	27	Kopreski et al. (2001), Clin. Chem. 47: 362, abstract 9.	<input type="checkbox"/>
	28	Pelosi et al. (2006), Virchows Arch. 448: 7-15.	<input type="checkbox"/>
	29	Tahara et al. (1999), Oncogene 18: 1561-1567.	<input type="checkbox"/>
	30	Dasi et al. (2001), Lab. Investigation 81: 767-769.	<input type="checkbox"/>
	31	Hasselmann et al. (2001), Oncol. Rep. 8: 115-118.	<input type="checkbox"/>
	32	Ng et al. (2002), Clin. Chem. 48: 1212-1217.	<input type="checkbox"/>
	33	Chen et al. (2000), Clin. Cancer Res. 6: 3823-3826.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10658873
Filing Date	2003-09-05
First Named Inventor	Michael S. Kopreski
Art Unit	1634
Examiner Name	Lu, Frank Wei Min
Attorney Docket Number	00-1312-K

/F./	34	Silva et al. (2001), Clin. Cancer Res. 7: 2821-2825.	<input type="checkbox"/>
	35	Silva et al. (2001), Oncol. Rep. 8: 693-696.	<input type="checkbox"/>
	36	Gal et al. (2001), Ann. N. Y. Acad. Sci. 945: 192-194.	<input type="checkbox"/>
	37	Durie et al. (2000), Acta Oncol. 39: 789-796.	<input type="checkbox"/>
	38	Miura et al. (2003), Oncology 64: 430-434.	<input type="checkbox"/>
	39	Wong et al. (2004), J. Clin. Pathol. 57: 766-768.	<input type="checkbox"/>
	40	Ma et al. (2007), Haematologica 92: 170-175.	<input type="checkbox"/>
	41	Arcari et al. (1984), Nucleic Acids Res. 12: 9179-9189.	<input type="checkbox"/>
	42	Rykova et al. (2006), Ann. N. Y. Acad. Sci. 1075: 328-333.	<input type="checkbox"/>
	43	Hernandez et al. (1999), Leukemia 13: 2087-2093.	<input type="checkbox"/>
	44	Zhou et al. (1998), Clin. Cancer Res. 4: 1631-1640.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10658873
Filing Date	2003-09-05
First Named Inventor	Michael S. Kopreski
Art Unit	1634
Examiner Name	Lu, Frank Wei Min
Attorney Docket Number	00-1312-K

/F.L./	45	Zhou et al. (2001), Breast Cancer Research and Treatment 66: 217-224.	<input type="checkbox"/>
↓	46	Press et al. (1990), Oncogene 5: 953-962.	<input type="checkbox"/>
	47	Ng et al. (2003), Proc. Natl. Acad. Sci. U. S. A. 100: 4748-4753.	<input type="checkbox"/>
	48	Baircy et al. (2002), Arch. Pathol. Lab. Med. 126: 574-576.	<input type="checkbox"/>
/F.L./	49	Gilmour et al. (2001), Cancer Res. 61: 2169-2716.	<input type="checkbox"/>
/F.L./	50	Reinhold et al. (2001), Clin. Chem. 47: 369, abstract 50.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Frank Lu/	Date Considered	12/22/2009
--------------------	------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.